Search for a trial

Efficacy and Cost Efficacy of Prophylactic treatment with Antibiotics during concomitant chemoradiotherapy in patients with locally advanced head and neck cancer to prevent Aspiration Pneumonia. A randomized phase II-III study

To observe a decrease in number of definite and/or suspected pneumonia after prophylactic treatment with antibiotics during CRT in patients with LAHNC.To observe a decrease in the number of admissions in the hospital To observe a decrease in the…

Evaluation of the effect of psycho-oncological intervention on well-being of patients with advanced prostate cancer on LHRH analogs and their partners.
A randomized controlled pilot study.

To asses the feasibility of conducting a larger trial to evaluate the effect of a psychological intervention on well-being of patients on LHRH analogs in the treatment of prostate cancer and their partners.

An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First Line Therapy in Patients with Advanced Nonsquamous Non Small Cell Lung Carcinoma

The primary objective of this study is to evaluate the hypothesis that cixutumumab given in combination with cisplatin and pemetrexed is superior to cisplatin and pemetrexed as first-line therapy for patients with advanced nonsquamous non-small cell…

A randomised, double-blind, active-controlled, double-dummy, parallel group study to determine the safety and efficacy of oxycodone / naloxone prolonged release tablets in subjects with moderate to severe, chronic cancer pain

To determine the improvement in symptoms of constipation in subjects receiving treatment with oxycodone/naloxone prolonged release tablets (OXN) compared to subjects receiving oxycodone prolonged release tablets (OXY) based on the Bowel Function…

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Cancer-Related Pain, Followed by an Open-Label Extension Phase

The objective of this study is to evaluate the safe use of JNJ-42160443 compared to placebo and to demonstrate whether patients JNJ-42160443 will, in addition to their standard treatment for pain, more pain relief than more patients receiving…

A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult patient with EGFR wild-type, ALK rearrangement negative locally advanced/metastatic non-small cell lung cancer.

The aim of this prospective, multicentre randomized phase II study is to evaluate the safety and efficacy of the combination of capmatinib and spartalizumab in subjects with EGFR weight (for exon 19 deletions and exon 21 L858R substitution mutations…

A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B

This study has been transitioned to CTIS with ID 2023-506385-30-00 check the CTIS register for the current data. Primary Part 1:-To evaluate ORR in participants treated with MK-4280A plus EV (Arm A), MK-7684A plus EV (Arm B), and pembrolizumab plus…

A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Coformulated
quavonlimab (MK-1308)/pembrolizumab) Versus Other Treatments in
Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient
(dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)

This study has been transitioned to CTIS with ID 2022-502100-70-00 check the CTIS register for the current data. The aim of this research is:1. To test the safety of MK-1308A, MK-4280A, MK-7684A and MK 4830 + pembrolizumab against pembrolizumab as…

A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined with Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma with PD-L1 Expressing Tumors (PROPEL-36)

In patients who are aged 18 years and older with recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC)and positive programmed cell death ligand1 (PD-L1)expression (defined by combined positive score [CPS]*1) who have not received…

Two-fraction Ultra-hypofractionated Radiotherapy with Focal Boost for low- and intermediate risk, localized prostate cancer (TURBO):phase II, randomized controlled clinical trial

To assess non-inferiority of treating patients with localized, intermediate risk prostate cancer in two fractions of 12 Gray (Gy) with a boost to the gross tumor volume of 13.5 Gy per fraction in 8 days, as compared to standard care (36.25 Gy in…

A Randomized, Multicentre, Open-Label Controlled Phase II Trial of Foxy-5 as Neo-Adjuvant Therapy in Subjects with Wnt-5a Low Colon Cancer.

Primary Objectives* To assess the safety and tolerability of Foxy-5 in subjects with colon cancer.* To assess circulating tumour DNA (ctDNA) in plasma as a surrogate parameter for disease recurrences in subjects with Wnt-5a low colon cancer treated…